---
Licensing Partnerships

Asset-1

The Status Quo Just changed

People suffering from addiction are frustrated with the status quo and are desperately looking for better options. When millions of people around the globe watched Netflix’s ‘How To Change Your Mind’, their world shifted on its axis when they realized a better option (psychedelic-assisted therapy) is not only being researched, but is actually being provided, right now! 

So many people came to this realization when the docuseries launched, our website servers crashed from the volume of traffic. Awakn featured on the show as the only psychedelic company actively providing Psychedelic-assisted therapy. 

This surge in patient demand accelerated the Licensing Partnership launch and as you may have seen in recent press releases, we announced the first two License Partners with many more to come. 

All this is happening inside an ecosystem that is rapidly changing to make many forms of psychedelic-assisted therapy legal and accessible, as evidenced by the Biden administration planning for the anticipated FDA approval of both MDMA and psilocybin in less than two years. 

What is your preference: wait 2 years to begin the process of integrating into your practice what patients want now, or, join the movement today to be ahead of the curve for what's coming in less than two years?  

Awakn’s Licensing Partnerships

Alcohol Use Disorder (AUD) is a devastatingly serious condition which affects 5% of the global population, that’s approximately 390 million people and it results in more than 5% of all deaths globally.

Treatment rates are very low, in the U.S. it is believed that only 8% of those suffering from AUD seek out treatment and from those few that do, 75% of them will relapse within the first 12 months. The pandemic has resulted in more people resorting to alcohol and the rates of addiction are increasing at alarming rates.

Treating addiction effectively is very difficult and there has been very little innovation in the last number of decades. We understand that addiction treatment providers need to be equipped with new effective tools to treat their clients the way they want to.

Awakn has answered this call with a new effective treatment that has been proven to work.

What is Awakn’s Treatment?

1

Awakn is providing to its licensed partners a proprietary ketamine-assisted therapy for the treatment of AUD. It is a revolutionary therapeutics treatment package.

2

It is the only therapeutics package for ketamine and therapy validated in a clinical trial and has been proven to be more effective than any other addiction treatment currently available.

3

Result from the clinical trial show; 86% abstinence at 6 months post treatment. In context, the average rate of abstinence prior to the treatment was 2%.

4

The protocol has been designed to be delivered by low intensity therapists.

5

It can be delivered at a higher margin and with greater efficacy.

What is the science behind it?

  • Four-armed Phase II a/b clinical trial for reducing relapse in alcohol use disorder with Ketamine-assisted therapy.
  • The research was funded by the UK State (Medical Research Council) who are also funding 66% of the Phase III trial.
  • Led by world renowned Ketamine expert Prof. Celia Morgan
  • N=96
  • Published: January 2021 in the American Journal of Psychiatry
  • Full paper can be found here.
Licensing-Partnershipimage2

Our Results

Conclusions

Primary Outcomes


1. KARE therapy significantly increased abstinence over all other groups.
2. Odds ratio of relapse was reduced with the KARE therapy.

Secondary Outcomes


1. Ketamine groups showed increased liver function across several markers.
2. Ketamine groups saw reduced depression and anhedonia (inability to experience pleasure) at 3 months.

Exploratory Analysis 



Heavy drinking days were reduced in the KARE group compared to all other groups.

Safety


Ketamine was well tolerated and had a good safety profile, adverse events were predominantly mild and only  reported by 8/96 patients. No serious adverse events happened.

Client Quotes

What does a License partner get?

Access-2

Access to Awakn’s Proprietary IP

  • Access to the Ketamine-assisted therapy treatment protocol
  • Access to the Ketamine-assisted therapy treatment manual
  • Access to client testimonials for marketing support
Learning-Platform

Training of your Key Staff

  • Medical Doctors, Physicians 
  • Medical staff including nurses and PAs
  • Psychotherapists, counsellors
Staff-Training

Systems:

  • eLearning platform to deliver training of your key staff
  • eHealth platform to efficiently deliver Awakn KARE therapy by your key staff
  • Data and Analytics on training and performance of your key staff, efficacy of therapy, and anonymised benchmarking
Clinic-Design

Set and Setting – Clinic Design

  • Best practices design package for creating the right environment to deliver the ketamine-assisted therapy
  • Bespoke design package for your existing clinic

What does a License partner get?

Access-2

Access to Awakn’s Proprietary IP

  • Access to the Ketamine-assisted therapy treatment protocol
  • Access to the Ketamine-assisted therapy treatment manual
  • Access to client testimonials for marketing support
Learning-Platform

Training of your Key Staff

  • Medical Doctors, Physicians 
  • Medical staff including nurses and PAs
  • Psychotherapists, counsellors
Staff-Training

Systems:

  • eLearning platform to deliver training of your key staff
  • eHealth platform to efficiently deliver Awakn KARE therapy by your key staff
  • Data and Analytics on training and performance of your key staff, efficacy of therapy, and anonymised benchmarking
Clinic-Design

Scene and Setting – Clinic Design

  • Best practices design package for creating the right environment to deliver the ketamine-assisted therapy
  • Bespoke design package for your existing clinic

Existing Licensing Partners

logodd
logo2

World leading Expert team

Awakn’s treatment and its training has been designed by the world’s leading experts in addiction, psychedelics, psychiatry, and psychology.

Psychedelics are transforming all of healthcare, including addiction medicine. Now is the time to join the revolution and help create the new ecosystem to deliver the breakthrough therapies.

Awakn_logo_corp

MAIN OFFICE
18 Dukes Road,
London WC1H 9PY, United Kingdom

UK OFFICE
1 Regent Street, Bristol, BS8 4HW, United Kingdom

© 2021 Awakn Life Sciences Corp      |      Privacy Policy      |      Appropriate Use Policy

Back to top Arrow